SCHEMBL28021678

SCHEMBL28021678

CCC(=O)Nc1ccc(S(=O)(=O)c2nc(Nc3cc(C)n[nH]3)cc(OC)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.45
▸ KMT2A Q03164 4/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ GAA P10253 1/20 0.42
▸ POLB P06746 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ HTT P42858 2/20 0.41
▸ AURKA O14965 2/20 0.41
▸ AURKB Q96GD4 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ THRB P10828 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ AKT1 P31749 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28021626 0.86 ATM (0.46) ATMKMT2AALDH1A1MEN1POLB
SCHEMBL28021591 0.84 AURKB (0.51) ATMKMT2AALDH1A1MEN1GAA
SCHEMBL28021603 0.82 ALDH1A1 (0.42) ATMKMT2AALDH1A1MEN1MAPT
SCHEMBL28549342 0.76 ACHE (0.48) KMT2AALDH1A1MEN1POLBKDM4E
SCHEMBL28021607 0.76 SLC2A1 (0.44) KMT2AALDH1A1MEN1GAAKDM4E
SCHEMBL28022078 0.76 PKM (0.44) KMT2AALDH1A1MEN1GAAPOLB
SCHEMBL28565368 0.75 AURKB (0.44) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL28022116 0.75 ADORA1 (0.47) KMT2AALDH1A1MEN1GAAPOLB
SCHEMBL28557357 0.73 AURKB (0.49) KMT2AALDH1A1MEN1POLBKDM4E
SCHEMBL28022048 0.73 AURKA (0.46) ALDH1A1POLBKDM4EMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback